Beckman Coulter Buys Out Royalty Obligation for Preeclamps... ( Initiates Clinical Trials Pha...)

Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers

Date:8/18/2008

Initiates Clinical Trials Phase of Test Development Program

ORANGE COUNTY, Calif., Aug. 18 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it signed an agreement to buy out its U.S. royalty obligation to Nephromics LLC, a Chestnut Hill, Mass.-based company focused on women's health. The license is for tests related to the detection, monitoring and risk assessment of preeclampsia, a leading cause of maternal death. In addition, Beckman Coulter obtained rights to acquire the worldwide diagnostics assets of Nephromics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

"Currently, there are no specific in vitro diagnostic tests for preeclampsia, even though the disease threatens the lives of thousands of women and their babies, and places a significant burden on healthcare systems worldwide," said Mike Whelan, vice president of Beckman Coulter's High Sensitivity Testing Business Group. "We expect that, once we complete our development program, these tests will help improve the outcomes of at-risk pregnancies. It is a powerful example of our commitment to provide clinical laboratories with the tools that improve patient health and reduce the cost of care. Our expectations for diagnostic testing related to maternal and fetal well-being leads us to believe that buying out our U.S. royalty obligation will create substantial value for our shareholders."

Beckman Coulter has initiated the clinical trial phase of its test development program. The new tests, expected to be useful as an aid in helping physicians diagnose preeclampsia, are being developed for use on the company's family of UniCel(R)
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
4. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
5. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
6. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
7. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
8. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
11. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36

Post Your Comments:

Beckman Coulter Buys Out Royalty Obligation for Preeclamps...( Initiates Clinical Trials Pha...),Health